Juliana Calheiros

LAQV/REQUIMTE Associated Laboratory For Green Chemistry Of The Network Of Chemistry And Technology
Porto, 4050313, Portugal

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Exploring the Anticancer Properties of 1,2,3-Triazole-Substituted Andrographolide Derivatives.

Exploring the Anticancer Properties of 1,2,3-Triazole-Substituted Andrographolide Derivatives.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: April 16, 2025

A first-in-class inhibitor of homologous recombination DNA repair counteracts tumour growth, metastasis and therapeutic resistance in pancreatic cancer.

A first-in-class inhibitor of homologous recombination DNA repair counteracts tumour growth, metastasis and therapeutic resistance in pancreatic cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: December 27, 2024

Antitumor Activity of the Xanthonoside XGAc in Triple-Negative Breast, Ovarian and Pancreatic Cancer by Inhibiting DNA Repair.

Antitumor Activity of the Xanthonoside XGAc in Triple-Negative Breast, Ovarian and Pancreatic Cancer by Inhibiting DNA Repair.

Journal: Cancers

Published: October 06, 2023

Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53.

Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53.

Journal: Biochimica et biophysica acta. Reviews on cancer

Published: April 21, 2023

Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target.

Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target.

Journal: Cancers

Published: May 14, 2021

Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance.

Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance.

Journal: Cancers

Published: March 01, 2021

BBIT20 inhibits homologous DNA repair with disruption of the BRCA1-BARD1 interaction in breast and ovarian cancer.

BBIT20 inhibits homologous DNA repair with disruption of the BRCA1-BARD1 interaction in breast and ovarian cancer.

Journal: British journal of pharmacology

Published: January 24, 2021

A selective p53 activator and anticancer agent to improve colorectal cancer therapy.

A selective p53 activator and anticancer agent to improve colorectal cancer therapy.

Journal: Cell reports

Published: July 30, 2020

BRCA1/P53: Two strengths in cancer chemoprevention.

BRCA1/P53: Two strengths in cancer chemoprevention.

Journal: Biochimica et biophysica acta. Reviews on cancer

Published: December 10, 2019

SLMP53-1 Inhibits Tumor Cell Growth through Regulation of Glucose Metabolism and Angiogenesis in a P53-Dependent Manner.

SLMP53-1 Inhibits Tumor Cell Growth through Regulation of Glucose Metabolism and Angiogenesis in a P53-Dependent Manner.

Journal: International journal of molecular sciences

Published: November 28, 2019

Carcinoembryonic antigen carrying SLeX as a new biomarker of more aggressive gastric carcinomas.

Carcinoembryonic antigen carrying SLeX as a new biomarker of more aggressive gastric carcinomas.

Journal: Theranostics

Published: August 09, 2019

Showing 1-11 of 11

Last Updated: 09/26/2026